Sidoti initiated coverage on Co-Diagnostics with a new price target
$CODX
Medical/Dental Instruments
Health Care
Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00
Get the next $CODX alert in real time by email
Get the next $CODX alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CODX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2022 | $5.00 | Buy → Neutral | Sidoti |
| 12/29/2021 | $14.00 | Buy | Sidoti |
| 11/12/2021 | $16.00 → $15.00 | Buy | HC Wainwright & Co. |
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 millionOperating expenses of $43.0 million decreased by 5
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY, March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025.
Co-Diagnostics downgraded by Sidoti with a new price target
Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00
Sidoti initiated coverage on Co-Diagnostics with a new price target
Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target
HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously
Chief Financial Officer Brown Brian Lee was granted 134,167 shares and returned $41,224 worth of shares to the company (40,816 units at $1.01), increasing direct ownership by 29% to 419,905 units (SEC Form 4)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
President Abbott Richard David was granted 20,000 shares and returned $6,146 worth of shares to the company (6,085 units at $1.01) (SEC Form 4)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
Chief Executive Officer Egan Dwight H was granted 163,333 shares and returned $50,186 worth of shares to the company (49,689 units at $1.01), increasing direct ownership by 28% to 522,858 units (SEC Form 4)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
SEC Form 10-K filed by Co-Diagnostics Inc.
10-K - Co-Diagnostics, Inc. (0001692415) (Filer)
Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
Co-Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com
Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer
SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i
Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer
SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 millionOperating expenses of $43.0 million decreased by 5
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results: Revenue of $0.6 million, which declined from $2.5 million during the prior year primarily due to timing of grant revenue recognition. Grant revenue totaled $0.4 million while product revenue totaled $0.2 millionOperating expenses of $10.6 million decreased by 5.0% from th
SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)